Rova-T R&D Program Discontinued Following Poor Results in Lung Cancer Trial - Monthly Prescribing Reference

Rova-T R&D Program Discontinued Following Poor Results in Lung Cancer Trial  Monthly Prescribing Reference

AbbVie has announced that the research and development program for its investigational drug, Rova-T (rovalpituzumab tesirine), for advanced small-cell lung ...